Virax Biolabs Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025

Reuters08-26
<a href="https://laohu8.com/S/VRAX">Virax Biolabs</a> Group Ltd. Partners with Emory University for Clinical Studies on ViraxImmune™; Prepares for FDA Pre-Submission Meeting in September 2025

Virax Biolabs Group Ltd., a biotechnology company specializing in immune response detection and diagnostics, has announced a partnership with Emory University's Center for the Advancement of Diagnostics for a Just Society to conduct clinical studies of their proprietary T cell testing technology, ViraxImmune™. These studies will focus on immune profiling in individuals with post-viral syndromes, specifically targeting post-acute sequelae of SARS-CoV-2, also known as long COVID. The collaboration is set to generate clinical data to support Virax's planned regulatory submissions and potential commercial rollout. The results of these studies have not yet been presented. Additionally, this partnership aligns with Virax's preparations for a pre-submission meeting with the U.S. Food and Drug Administration in early September 2025 to discuss the regulatory pathway for ViraxImmune™.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA58084) on August 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment